DISEASE CHARACTERISTICS:

• Planned allogeneic stem cell transplantation for one of the following diagnoses:

  • Refractory anemia with excess blasts (RAEB)
  • Refectory anemia with excess blast in transformation (RAEB-t)
  • Chronic myelogenous leukemia (CML) beyond chronic phase
  • Primary refractory acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL)
  • AML or ALL beyond first remission
  • Therapy-related AML at any stage
  • Philadelphia chromosome-positive ALL at any stage

  • Acute leukemia at any stage arising from myelodysplastic or myeloproliferative syndromes, including:

    • Chronic myelomonocytic leukemia
    • CML
    • Polycythemia vera
    • Essential thrombocytosis
    • Angiogenic myeloid metaplasia with myelofibrosis
• Patient and donor must both express an HLA-allele for which it is possible to generate WT1-specific clones

• No grade III or IV graft-versus-host disease unresponsive to therapy or requiring therapy with any of the following:

  • Prednisone or corticosteroid equivalent > 0.5 mg/kg/day
  • Anti-CD3 monoclonal antibody
  • Other treatments resulting in T-cell inactivation or ablation
• No graft rejection or failure
• Able and willing to provide blood and bone marrow samples
• Highest-risk disease group: More than 5% blasts detected in bone marrow or peripheral blood just prior to or at time of transplantation

• Relapsed-disease group: One of the following types of relapsed disease after transplantation:

  • Morphologic relapse defined by one or more of the following:

    • Peripheral blasts in absence of growth factor therapy
    • Bone marrow blasts more than 5% of nucleated cells
    • Extramedullary chloroma or granulocytic sarcoma
  • Cells with abnormal immunophenotype and consistent with leukemia relapse in the peripheral blood or bone marrow detected by flow cytometry
  • Cytogenetic relapse defined as the appearance in 1 or more metaphases from peripheral blood or bone marrow of either a non-constitutional cytogenetic abnormality identified in at least 1 cytogenetic study performed before transplantation or a new abnormality known to be associated with leukemia
  • An increase in the number of Philadelphia chromosome metaphases from bone marrow or peripheral blood between 2 consecutive samples in patients with CML
  • An increase in the percentage of bcr-abl positive cells by fluorescence in situ hybridization between 2 consecutive samples

  • Molecular relapse defined as one of the following:

    • 1 or more positive PCR assays for clonotypic immunoglobulin heavy chain (IgH) gene rearrangement for patients with B-cell ALL
    • 1 or more positive PCR assays for T-cell receptor (TCR) gene rearrangement for patients with T-cell ALL
    • 1 or more positive post-transplantation reverse transcription PCR assays for bcr-abl mRNA fusion transcripts in patients with bcr-abl-positive ALL
    • A positive PCR assay for bcr-abl mRNA fusion transcript that quantitatively increases by > 1 order of magnitude on a subsequent sample in patients with CML

PATIENT CHARACTERISTICS:

Age

• 75 and under

Performance status

• Karnofsky 40-100% OR
• Lansky 40-100%

Life expectancy

• Not specified

Other

• No pre-existing nonhematopoietic organ toxicity greater than grade 2

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics

Chemotherapy

• No concurrent hydroxyurea

Endocrine therapy

• See Disease Characteristics

• Concurrent immunosuppressive therapy for graft-versus-host disease (GVHD) allowed if meets 1 of the following criteria:

  • Corticosteroid dose can be tapered to no more than 0.5 mg/kg/day without an increase to grade III or IV acute GVHD or progression of chronic GVHD

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• No other concurrent agents that may interfere with the function or survival of infused CTL clones